Latest News

September 11, 2014
Bacteria that normally live in and upon us have genetic blueprints that enable them to make thousands of molecules that act like drugs, and some of these molecules might serve as the basis for new human therapeutics, according to UCSF researchers.
June 18, 2014
The Ras protein is one of the most common and deadly drivers of cancer, yet it has eluded any drug therapies for decades. Scientists are getting close to changing that.
June 03, 2014
The New York Times Health for Tomorrow conference, held at UCSF, featured experts from the University of California and across the country, addressing the changing landscape of health care.
May 05, 2014
The Food and Drug Administration has selected UCSF as the site of a new regulatory science center on the West Coast. The center aims to spur innovative approaches in drug development that will support the FDA’s ability to evaluate and approve safe and effective new medications.
April 21, 2014
Despite its potentially harmful effects in children, codeine continues to be prescribed in U.S. emergency rooms, according to new research from UCSF Benioff Children’s Hospital San Francisco.
April 17, 2014
Nobel Prize winner Stanley Prusiner is closing in on better treatments for Alzheimer's, Parkinson's and other brain diseases, and an unlikely new partnership will get him there faster.
March 05, 2014
UCSF is changing the way you think about your neighborhood drugstore by putting the pharmacist front and center – not just in the store, but also on your health care team.
January 24, 2014
A new analysis of animal studies on cholesterol-lowering statins by UC San Francisco researchers found that non-industry studies had results that favored the drugs even more than studies funded by industry.
November 20, 2013
The protein in cells that most often drives the development of cancers has eluded scientists’ efforts to block it for three decades — until now.
July 18, 2013
UCSF researchers have found a way to knock down cancers caused by a tumor-driving protein called “myc,” paving the way for patients with myc-driven cancers to enroll in clinical trials for experimental treatments.

Pages